Objectives: To determine whether there is greater risk of initiation of oxybutynin to treat urinary incontinence (UI) after initiation of medicines reported to be associated with UI.
Design: Prescription sequence symmetry analysis (PSSA).
Setting: Administrative claims data from the Australian Government Department of Veterans' Affairs.
Participants: Individuals who initiated oxybutynin and a medicine reported to be associated with UI in a 12-month period.
Measurements: Between January 1, 2001, and December 31, 2011, the distribution of incident dispensing of medicines reported to be associated with UI (prazosin, diuretics, calcium channel blockers (CCBs), angiotensin-converting enzyme inhibitors (ACEIs), angiotensin receptor blockers (ARBs), hormone replacement therapy (HRT), opioid analgesics, anticonvulsants, levodopa, antipsychotics, sedatives, selective serotonin reuptake inhibitors (SSRIs), venlafaxine, anticholinesterases) was assessed before and after incident dispensing of oxybutynin (to treat UI). Crude and adjusted sequence ratios (ASRs) with 95% confidence intervals (CIs) were calculated.
Results: Significant associations between initiation of CCBs, ACEIs, ARBs, and hypnotic-sedatives and subsequent initiation of oxybutynin were found. ASRs ranged from 1.28 (95% CI = 1.19-1.39) for ACEIs to 1.59 (95% CI = 1.29-1.96) for verapamil. In women, there was greater risk of initiation of oxybutynin after prazosin (ASR = 1.84, 95% CI = 1.29-2.63) and HRT (ASR = 1.54, 95% CI = 1.42-1.67) initiation. PSSA showed no significant association with initiation of opioids, anticonvulsants, levodopa, SSRIs, venlafaxine, or anticholinesterases and subsequent initiation of oxybutynin.
Conclusion: This study highlights the potential for initiation of commonly used medicines to be associated with subsequent initiation of oxybutynin to treat UI. Greater awareness of the potential for medicines to contribute to UI is required.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1111/jgs.12741 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Trends in Medicare Coverage of Overactive Bladder Medications in the United States.
Urogynecology (Phila)
December 2024
From the Urogynecology and Reconstructive Pelvic Surgery, MedStar Washington Hospital Center/Georgetown University, Washington, DC.
Importance: Strong evidence demonstrates long-term cognitive decline associated with anticholinergics. While prevalent among older populations, medical management of overactive bladder (OAB) is dictated by insurance coverage rather than medical provider and patient preferences.
Objective: The aim of this study was to assess Medicare insurance plan coverage for select OAB medications and evaluate coverage of preferred medications to medications with a greater risk of cognitive dysfunction.
Long-term efficacy of Mirabegron-anticholinergic combination in paediatric neurogenic bladder.
J Pediatr Urol
January 2025
Department of Women and Children's Health, School of Life Course Sciences, Kings College London, London, UK; Children's Bladder Service, Evelina London Children's Hospital, Westminster Bridge Road, London, SE1 7EH, UK.
Introduction: The Mirabegron-anticholinergic (MAC) combination has proven effective as a step-up strategy in managing paediatric neurogenic bladder following anticholinergic medication and botulinum toxin (BTX) therapy. This study assesses the long-term efficacy of MAC in children with neurogenic bladder.
Patients And Methods: A retrospective chart review was conducted from 2015 to 2023, including consecutive paediatric patients receiving Mirabegron (25/50 mg) with an anticholinergic agent (solifenacin 16, tolterodine 7, oxybutynin 7, trospium 1).
Trends in Overactive Bladder Therapy: Associations Between Clinical Care Pathways, Practice Guidelines, and Therapy Utilization Patterns.
Neurourol Urodyn
November 2024
Department of Urology, Stanford University, Stanford, California, USA.
Article Synopsis
- Overactive bladder (OAB) is a long-term condition affecting health and finances, and guidelines were created to improve its management, but the effectiveness of these guidelines remains unclear.
- A study analyzed data from a national health claims database (Optum) between 2013 and 2018 to evaluate trends in OAB treatment, focusing on medication and minimally invasive therapies post-2014 guideline updates.
- The research included over 1.8 million patients, revealing a significant increase in new OAB diagnoses (369%) and providing insights into therapy utilization patterns based on various demographic factors.
The Management of Children and Adolescents with Overactive Bladder Refractory to Treatment with Parasacral Transcutaneous Electrical Nerve Stimulation.
Int Braz J Urol
November 2024
Centro de Distúrbios Urinários Infantis (CEDIMI), Escola Bahiana de Medicina e Saúde Pública, Salvador, Bahia, Brasil.
Article Synopsis
- - This study investigated how children aged 4-17 with overactive bladder (OAB) responded to various treatments after not completing sessions of parasacral TENS (pTENS).
- - Out of 30 children, 70% received single treatments, with 57% achieving complete symptom resolution and 28% having partial success, while 30% still faced bothersome symptoms.
- - Results showed that more intensive therapies led to better outcomes, with a significant decrease in Dysfunctional Voiding Scoring System scores and an increase in patient satisfaction reported through Visual Analogue Scale scores.
Urinary Incontinence Medications: Patient-Initiated Concerns in Primary Care.
Urogynecology (Phila)
June 2024
From the Department of Medicine, Medical College of Wisconsin, Milwaukee, WI.
Importance: Guideline-recommended medications for overactive bladder and urge urinary incontinence (OAB/UUI) are effective but have high costs and side effects. Little is known about patient concerns regarding these medications when prescribed by their primary care providers (PCPs).
Objective: The aim of the study was to describe PCP-patient interactions when prescribing medications for OAB/UUI, specifically clinical concerns, cost and authorization issues, and mode of communication for these interactions.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!